Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy
OBJECTIVES: This study designed to compare the efficacy, and tolerability of heme-iron OptiFer® to ferrous fumarate in the treatment of iron deficiency anemia during pregnancy. STUDY DESIGN: Two hundred and thirty-four (234) women with iron deficiency anemia during pregnancy were included in this...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Network
2022-03-01
|
| Series: | Gynecology Obstetrics & Reproductive Medicine |
| Subjects: | |
| Online Access: | https://gorm.com.tr/index.php/GORM/article/view/1147 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823857354825793536 |
|---|---|
| author | Ibrahim A. Abdelazim Mohannad AbuFaza Soud M. Al-Ajmi Osama O. Amer Svetlana Shikanova Bakyt Karimova |
| author_facet | Ibrahim A. Abdelazim Mohannad AbuFaza Soud M. Al-Ajmi Osama O. Amer Svetlana Shikanova Bakyt Karimova |
| author_sort | Ibrahim A. Abdelazim |
| collection | DOAJ |
| description |
OBJECTIVES: This study designed to compare the efficacy, and tolerability of heme-iron OptiFer® to ferrous fumarate in the treatment of iron deficiency anemia during pregnancy.
STUDY DESIGN: Two hundred and thirty-four (234) women with iron deficiency anemia during pregnancy were included in this study; 121 women in the heme-iron OptiFer® group, and 113 women in the ferrous fumarate group. Women in the heme-iron OptiFer® group received OptiFer® tablets twice daily for ≥3 months then once daily as a maintenance dose. Women in the ferrous fumarate group received 350 mg oral ferrous fumarate once daily for ≥3 months. The pre-treatment ferritin, hemoglobin, red blood cells-mean corpuscular volume, and red blood cells-mean corpuscular hemoglobin were compared by the post-treatment values in the two studies.
RESULTS: The post-treatment hemoglobin and ferritin were significantly high in the heme-iron OptiFer® group (11.2±7.1 gm/dL and 112.8±54.8 ug/l, respectively) compared to the ferrous fumarate group (10.9 ±5.1 and 89.9±43.3, respectively; p=0.0002 and p=0.006; respectively). The post-treatment red blood cells-mean corpuscular volume and red blood cells-mean corpuscular hemoglobin were significantly high in the heme-iron OptiFer® group (92.0±4.1 fl and 31.9±6.2 pg, respectively) compared to the ferrous fumarate group (87.7±2.9 and 28.5±4.7, respectively; p=0.0001 and p=0.001, respectively). The rates of poor compliance and gastrointestinal intolerance were significantly high in the ferrous fumarate group compared to the heme-iron OptiFer® group (12.4% and 19.5%, respectively versus 3.3% and 2.5%, respectively), (p=0.01 and p=0.0001, respectively).
CONCLUSION: Heme-iron OptiFer® is an effective therapeutic option for the treatment of iron deficiency anemia during pregnancy with low side effects. heme-iron OptiFer® can be used in women who have low compliance, and/or gastrointestinal intolerance to conventional iron salts.
|
| format | Article |
| id | doaj-art-72d77e1be5b34ed381212ede96a3bdfe |
| institution | Kabale University |
| issn | 1300-4751 2602-4918 |
| language | English |
| publishDate | 2022-03-01 |
| publisher | Medical Network |
| record_format | Article |
| series | Gynecology Obstetrics & Reproductive Medicine |
| spelling | doaj-art-72d77e1be5b34ed381212ede96a3bdfe2025-02-11T21:14:45ZengMedical NetworkGynecology Obstetrics & Reproductive Medicine1300-47512602-49182022-03-0128110.21613/GORM.2020.1147Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy Ibrahim A. Abdelazim0Mohannad AbuFaza1Soud M. Al-Ajmi2Osama O. Amer3Svetlana Shikanova4Bakyt Karimova5Ain Shams University, Cairo, Egypt and Ahmadi hospital, Kuwait Oil Company (KOC).Ahmadi hospital, Kuwait Oil Company (Kuwait)Chief Clinical Officer Ahmadi Hospital, Kuwait Oil Company (Kuwait)Ghamra Military Hospital, Cairo, EgyptWest Kazakhstan Marat Ospanov Medical University, Aktobe, KazakhstanWest Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan OBJECTIVES: This study designed to compare the efficacy, and tolerability of heme-iron OptiFer® to ferrous fumarate in the treatment of iron deficiency anemia during pregnancy. STUDY DESIGN: Two hundred and thirty-four (234) women with iron deficiency anemia during pregnancy were included in this study; 121 women in the heme-iron OptiFer® group, and 113 women in the ferrous fumarate group. Women in the heme-iron OptiFer® group received OptiFer® tablets twice daily for ≥3 months then once daily as a maintenance dose. Women in the ferrous fumarate group received 350 mg oral ferrous fumarate once daily for ≥3 months. The pre-treatment ferritin, hemoglobin, red blood cells-mean corpuscular volume, and red blood cells-mean corpuscular hemoglobin were compared by the post-treatment values in the two studies. RESULTS: The post-treatment hemoglobin and ferritin were significantly high in the heme-iron OptiFer® group (11.2±7.1 gm/dL and 112.8±54.8 ug/l, respectively) compared to the ferrous fumarate group (10.9 ±5.1 and 89.9±43.3, respectively; p=0.0002 and p=0.006; respectively). The post-treatment red blood cells-mean corpuscular volume and red blood cells-mean corpuscular hemoglobin were significantly high in the heme-iron OptiFer® group (92.0±4.1 fl and 31.9±6.2 pg, respectively) compared to the ferrous fumarate group (87.7±2.9 and 28.5±4.7, respectively; p=0.0001 and p=0.001, respectively). The rates of poor compliance and gastrointestinal intolerance were significantly high in the ferrous fumarate group compared to the heme-iron OptiFer® group (12.4% and 19.5%, respectively versus 3.3% and 2.5%, respectively), (p=0.01 and p=0.0001, respectively). CONCLUSION: Heme-iron OptiFer® is an effective therapeutic option for the treatment of iron deficiency anemia during pregnancy with low side effects. heme-iron OptiFer® can be used in women who have low compliance, and/or gastrointestinal intolerance to conventional iron salts. https://gorm.com.tr/index.php/GORM/article/view/1147Heme-iron OptiFer®Iron deficiency anemiaPregnancy |
| spellingShingle | Ibrahim A. Abdelazim Mohannad AbuFaza Soud M. Al-Ajmi Osama O. Amer Svetlana Shikanova Bakyt Karimova Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy Gynecology Obstetrics & Reproductive Medicine Heme-iron OptiFer® Iron deficiency anemia Pregnancy |
| title | Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy |
| title_full | Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy |
| title_fullStr | Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy |
| title_full_unstemmed | Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy |
| title_short | Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy |
| title_sort | heme iron optifer r in the treatment of iron deficiency anemia during pregnancy |
| topic | Heme-iron OptiFer® Iron deficiency anemia Pregnancy |
| url | https://gorm.com.tr/index.php/GORM/article/view/1147 |
| work_keys_str_mv | AT ibrahimaabdelazim hemeironoptiferinthetreatmentofirondeficiencyanemiaduringpregnancy AT mohannadabufaza hemeironoptiferinthetreatmentofirondeficiencyanemiaduringpregnancy AT soudmalajmi hemeironoptiferinthetreatmentofirondeficiencyanemiaduringpregnancy AT osamaoamer hemeironoptiferinthetreatmentofirondeficiencyanemiaduringpregnancy AT svetlanashikanova hemeironoptiferinthetreatmentofirondeficiencyanemiaduringpregnancy AT bakytkarimova hemeironoptiferinthetreatmentofirondeficiencyanemiaduringpregnancy |